The aim of this study was to select the best approach for screening coeliac disease patients among populations with different grades of disease prevalence. 
Abstract
The aim of this study was to select the best approach for screening coeliac disease patients among populations with different grades of disease prevalence. The diagnostic performance was assessed of class A and G antigliadin antibodies and class A antiendomysium antibodies in 93 consecutive outpatients with suspected malabsorption, 44 of whom (47%) had coeliac disease according to duodenal histological tests. Class G antigliadin antibodies provided the worst diagnostic values, whereas a high diagnostic validity was found for the other two tests. The positive predictive value corrected for the disease prevalence expected in coeliac disease relatives (5%) and the general population (0.20/o) fell to 30% and <2% respectively for class A antigliadin antibodies, whereas it remained 100% for antiendomysium antibodies in both situations, providing an optimal value for their use as a screening test and as a valid alternative to duodenal biopsy when this is not feasible. The high cost of antiendomysium antibodies and the invasive nature of duodenal biopsy prevent them being used widely as screening procedures. A cost effective two step approach was simulated measuring class A antigliadin antibodies in all subjects of the target population (first step), and performing a confirmation test (antiendomysium antibodies or duodenal biopsy) only in subjects positive for antigliadin antibodies. The results show that such a procedure should be recommended only for subjects with an expected low disease prevalence -that is, 5% for coeliac disease relatives and 0O2% for the general population -as the positive predictive value was always 100% with an acceptable false negative rate (6% and 11% respectively), irrespective of which of the two confirmation tests was used. This approach avoids the use of the confirmation test in 63% and 89% of subjects respectively for the two The receiver operating characteristic analysis was also carried out to find out if using the two tests simultaneously results in a greater discriminant ability than using either test alone. For this purpose, we obtained a discriminant function using a linear discriminant analysis model, where the dependent variable was the diagnostic category (presence or absence of coeliac disease) and the independent variables were serum IgA-AGA and IgG-AGA. The receiver operating characteristic curve was obtained from the a posteriori probability of the discriminant function, and area under curve was calculated as described above. The predictivity of such a procedure has Both the specificity and positive predictive value of the two step procedure remained 100%, because no false positive results resulted from duodenal biopsy (gold standard test) or IgA-EMA. Table V shows that sensitivity was greater when biopsy was used as the confirmation test, and when lower IgA-AGA cut off points were chosen. Table VI shows high negative predictive value throughout the simulation, particularly in the case of a low prevalence of coeliac disease. The worse negative predictive value (92%) was seen when IgA-EMA were assessed in subjects with higher than 0d12 ELISA units IgA-AGA, in the case of 47% prevalence of coeliac disease. The proportion of subjects positive for the first step test, in whom the second step confirmation test was carried out, was higher at increased values of disease prevalence and at decreased IgA-AGA cut off points.
Discussion
Early withdrawal from gluten intake in patients with coeliac disease prevents the complications resulting from long standing disease and reduces the incidence of gastrointestinal malignancies, which occur with higher incidence than expected in coeliac disease patients.202'
The implementation of screening programmes to detect asymptomatic coeliac disease patients is, however, hampered by the fact that duodenal biopsy, which is the gold standard diagnostic procedure, is comparatively invasive and time consuming and cannot be used for some purposes, particularly in children.
The availability of improved techniques for measuring AGA in serum as markers for coeliac disease has provided the feasibility of screening programmes on wide series of high risk subjects22-27 and in the general We then simulated the screening of asymptomatic high risk subjects, in whom coeliac disease prevalence should be between 2 and 8%.2627 Considering an intermediate 5% prevalence of coeliac disease, IgA-AGA at a 0-08 ELISA units cut off point resulted in 13% positive predictive value, and 100% negative predictive value. This setting cannot justify a duodenal biopsy in asymptomatic IgA-AGA positive subjects especially when it is expected that there is low compliance to the test by such subjects. The detection of EMA as a second step confirmation test in IgA-AGA positive subjects would be the optimal procedure, causing a negligible reduction of the overall sensitivity (from 96 to 94%), but a considerable increase in specificity (from 66 to 100%), entailing a 6% false negative rate and avoiding the EMA test in 63% of the cases.
When we considered a 0-2% coeliac disease prevalence, simulating the expected prevalence in the general population,2 IgA-AGA at a 0-08 ELISA units cut off point resulted in a positive predictive value below 1%. In IgA-AGA positive subjects, duodenal biopsy is clearly not feasible, whereas detection of EMA is again the procedure of choice. If we used a higher cut off value for IgA-AGA (0-12 ELISA units), the detection of EMA resulted in 100% positive predictive value and a near 100% negative predictive value, entailing an 11% false negative rate, and avoiding EMA in 89% of the cases. This approach had the advantage of saving 87% of the cost by comparison with the use of EMA as a single step screening test.
The estimated diagnostic values of the two step procedure are affected by the design of our study, which used a sample of coeliac disease patients and a group of control patients with other gastrointestinal diseases. Because antigliadin antibodies can be found in patients with inflammatory bowel disease,32 we can hypothesise that the actual specificity of IgA-AGA would have been higher than we estimated, had we considered asymptomatic patients or subjects from the general population. Thus, both the overall false negative rate and the frequency of use of costly confirmation tests, such as EMA, should be actually lower than we estimated in running a screening programme based on the two step procedure that we have examined.
In conclusion, we have shown that the best diagnostic approach to the diagnosis of coeliac disease using serological screening tests changes according to the target population. In a gastroenterology clinic we suggest a single step procedure (duodenal biopsy) in patients with clinically suspected coeliac disease. In screening asymptomatic high risk relatives or subjects in the general population we suggest the use of IgA-AGA followed by the detection of EMA only in IgA-AGA positive subjects. This approach represents a compromise between the poor predictivity of AGA, the high cost of EMA, and the invasive nature of duodenal biopsy. 
